Achieving lipid goals in real life: the Dutch DISCOVERY study

DISCOVERY Netherlands was an open-label, randomised, multicentre study (D3560/L00003) designed to compare the effects of rosuvastatin with those of atorvastatin, simvastatin or pravastatin on low-density lipoprotein cholesterol (LDL-C) goal achievement in a primary care setting. Patients (n = 1,215) with type IIa or type IIb hypercholesterolaemia and cardiovascular risk of >20% or a history of coronary heart or other atherosclerotic vascular disease were randomised to receive treatment with rosuvastatin 10 mg (n = 621), atorvastatin 10 mg (n = 189), simvastatin 20 mg (n = 194) or pravastatin 40 mg (n = 211) for 12 weeks. Significantly, more patients achieved 1998 and 2003 European LDL-C goals with rosuvastatin than with other statins after 12 weeks (p < 0.001). Rosuvastatin reduced LDL-C and total cholesterol levels significantly more than other statins, both in patients who were statin-naive and in patients who had received previous statin treatment (p < 0.05). All treatments were similarly well tolerated. In conclusion, greater reductions in LDL-C were achieved with rosuvastatin compared with atorvastatin, simvastatin and pravastatin, enabling more patients to achieve European LDL-C goals.

Journal Ref. Bots AFE, Kastelein JJP, Discovery Netherlands I: Achieving lipid goals in real life: the Dutch DISCOVERY study. International Journal of Clinical Practice 2005, 59:1387-1394.
Intervention Drug - 12 week treatment with Rosuvastatin 10mg
Number of sites 152
Countries involved 1
Sample size 1215
Type of statistical analyses intention-to-treat but also post-hoc analyses
Risk of bias Overall: Unclear details
Participant characteristics Age: 60-62 (9.3-9.7)
Condition: Type 11a or 11b hypercholesterolaemia
Baseline severity: Fasting LDL-Cholesterol of >3.5 mmol/l if untreated or fasting LDL-C of >3.1 mmol/l if currently being treated with start dose of other lipid lowering therapy.
Duration of trial Unclear
Primary outcome Achieving European LDL-C goal (<3.0 mmol/l) at week 12
Effect Measures
Events Intervention Total Events Control Total Risk Diff.
468 621 110 189 17.16%
p < 0.001
Show Score Ranges


(shows median if more than one score was entered)

Elig. Recr. Setting Org. Int. Flex. Del. Flex. Adherence Follow-Up Prim. Out. Prim. An.
2 3 5 5 3 3 5 3 4